annb0t
Top 20
MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit ("Kit") for the preparation of PSMA-PET imaging[1] for prostate cancer. (PRNewsfoto/Telix Pharmaceuticals Limited)
Subject to regulatory approval, this Kit will enable use of a PSMA imaging product with a considerab...
>>> Read more: Telix Submits NDA for New Prostate Cancer Imaging Agent
Subject to regulatory approval, this Kit will enable use of a PSMA imaging product with a considerab...
>>> Read more: Telix Submits NDA for New Prostate Cancer Imaging Agent
